These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 14662555)

  • 41. [Clinical evaluation of treatment of psychoses with once-a-day phenothiazine doses].
    Sidorowicz S; Krakiewicz A; Wilska M
    Psychiatr Pol; 1979; 13(3):251-6. PubMed ID: 38469
    [No Abstract]   [Full Text] [Related]  

  • 42. [Depot Neuroleptic preparations in psychiatric practice (author's transl)].
    Svestka J; Bártová D; Cesková E; Rysánek R
    Cesk Psychiatr; 1981 Jun; 77(3):187-97. PubMed ID: 6119161
    [No Abstract]   [Full Text] [Related]  

  • 43. [Conditions for prolonged prescription of neuroleptics with reference to several clinical cases].
    Tholose A
    Ann Med Psychol (Paris); 1981; 139(8):894-9. PubMed ID: 6120672
    [No Abstract]   [Full Text] [Related]  

  • 44. Flupentixol in psychoses. Controlled clinical trial.
    Vinar O; Formánková M; Růzicka S; Taussigová D
    Act Nerv Super (Praha); 1968 Oct; 10(3):313-4. PubMed ID: 4883239
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical parable: mirthless merry-go-round.
    Martin IC
    Nurs Times; 1978 Aug; 74(34):1426-7. PubMed ID: 29282
    [No Abstract]   [Full Text] [Related]  

  • 46. Depot antipsychotic drugs revisited.
    Mannion L; Carney PA; Sloan D; Cody M
    Psychiatr Serv; 1998 Oct; 49(10):1361-2. PubMed ID: 9779918
    [No Abstract]   [Full Text] [Related]  

  • 47. One-year trial of the antipsychotic acridan compound, SK&F 14336.
    Bishop MP; Mason LB; Gallant DM; Bishop G
    Curr Ther Res Clin Exp; 1969 Jul; 11(7):447-55. PubMed ID: 4979993
    [No Abstract]   [Full Text] [Related]  

  • 48. Slow onset of CNS drugs: can changes in protein concentration account for the delay?
    Kuhar MJ; Joyce AR
    Trends Pharmacol Sci; 2001 Sep; 22(9):450-6. PubMed ID: 11543871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Searching for new approaches to antipsychotic therapy.
    King DJ
    J Psychopharmacol; 1992 Jan; 6(4):547-8. PubMed ID: 22291411
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
    Leucht S; Cipriani A; Spineli L; Mavridis D; Orey D; Richter F; Samara M; Barbui C; Engel RR; Geddes JR; Kissling W; Stapf MP; Lässig B; Salanti G; Davis JM
    Lancet; 2013 Sep; 382(9896):951-62. PubMed ID: 23810019
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.
    Leucht S; Busch R; Hamann J; Kissling W; Kane JM
    Biol Psychiatry; 2005 Jun; 57(12):1543-9. PubMed ID: 15953491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.
    Demjaha A; Murray RM; McGuire PK; Kapur S; Howes OD
    Am J Psychiatry; 2012 Nov; 169(11):1203-10. PubMed ID: 23034655
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study.
    Andreasen NC; Liu D; Ziebell S; Vora A; Ho BC
    Am J Psychiatry; 2013 Jun; 170(6):609-15. PubMed ID: 23558429
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
    Kane J; Honigfeld G; Singer J; Meltzer H
    Arch Gen Psychiatry; 1988 Sep; 45(9):789-96. PubMed ID: 3046553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
    Chouinard G; Jones BD
    Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM
    Neuropsychopharmacology; 2010 Jan; 35(2):581-90. PubMed ID: 19890258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
    Zedkova I; Dudova I; Urbanek T; Hrdlicka M
    Neuro Endocrinol Lett; 2011; 32(5):667-70. PubMed ID: 22167144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.
    Buchanan RW; Kreyenbuhl J; Kelly DL; Noel JM; Boggs DL; Fischer BA; Himelhoch S; Fang B; Peterson E; Aquino PR; Keller W;
    Schizophr Bull; 2010 Jan; 36(1):71-93. PubMed ID: 19955390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.
    Leucht S; Corves C; Arbter D; Engel RR; Li C; Davis JM
    Lancet; 2009 Jan; 373(9657):31-41. PubMed ID: 19058842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.